PLaybook
HOW WE DO IT
We select companies based on their scientific foundation, operational maturity, and ability to create long-term value in health and biotechnology.
Rather than sourcing isolated research projects, we focus on ventures with validated potential, committed founders and clear strategic opportunities.
Our goal is to participate in businesses capable of scaling responsibly and positioning themselves for future strategic transactions.
As a holding company and venture builder, we work side-by-side with our portfolio to strengthen governance, define priorities and support founders through complex decisions.
Our approach is centered on structure, discipline and market awareness: key elements for health and biotech companies operating in highly regulated environments.
By offering clarity, stability and strategic guidance, we help each venture progress with confidence.
Global standards shape the biotech market, and we help our companies align with them when it creates strategic advantage.
This includes intellectual property strategy, regulatory pathways, partnerships and access to specialized networks in relevant markets.
Our international outlook is pragmatic: we expand globally when it enhances valuations, visibility and future strategic options.
We support companies throughout their development by reinforcing scientific, operational and financial rigor.
Each venture advances under a clear roadmap, balancing innovation with disciplined execution and compliance.
This structured process prepares our companies to interact with corporate partners, investors and strategic acquirers with credibility.
Exit readiness is a central part of our philosophy.
From the beginning, we help our companies organize themselves to be attractive, transparent and technically sound for potential acquisitions.
Our experience across scientific, regulatory and business environments allows us to guide ventures toward high-quality exit opportunities: from strategic transactions to large-scale international M&A.
This approach supports long-term value creation and enables our portfolio to capitalize on the growing global demand for innovative health and biotech companies.